News
Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 ...
Eli Lilly’s legal actions against Empower Pharmacy and other compounding pharmacies come several months after the FDA ...
A WOMAN who weighed 12st 10lbs and was a size 16 decided to try the weight loss jab after struggling to stick to diets, but things weren’t as perfect as she’d hoped. Kathleen Smith, ...
Big Pharma has put a Houston pharmacy squarely in the crosshairs of its quest to weed out copycat versions of wildly popular ...
2don MSN
Eli Lilly ( LLY 3.84%) and Novo Nordisk ( NVO 2.01%) were early leaders in the development of GLP-1 agonists, and dominate the market. Research from MarketsandMarkets suggests that annual global sales ...
Eli Lilly is suing four telemedicine companies selling compounded versions of its blockbuster obesity drug Zepbound and its diabetes treatment Mounjaro, escalating its battle against ...
Eli Lilly (LLY) is scheduled to release its Q1 earnings on May 1, and analysts continue to stay positive, holding onto Buy ...
The pecking order of the obesity drug market is shifting. Eli Lilly , the $815 billion maker of blockbuster weight-loss drugs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback